The first-generation MDM2 inhibitor Nutlin-3 could inhibit androgen receptor-driven c-FLIP expression, resulting in apoptosis of PCa cells and enhancing the curative effect of chemotherapy. The gene discussed is AR; the disease is posterior cortical atrophy.